Edwards Lifesciences (EW)
Market Price (2/1/2026): $81.37 | Market Cap: $47.6 BilSector: Health Care | Industry: Health Care Equipment
Edwards Lifesciences (EW)
Market Price (2/1/2026): $81.37Market Cap: $47.6 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 28% | Weak multi-year price returns2Y Excs Rtn is -31%, 3Y Excs Rtn is -68% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 28x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 47x, P/EPrice/Earnings or Price/(Net Income) is 35x |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14% | Key risksEW key risks include [1] intense competition in its core TAVR and TMTT markets from major rivals, Show more. | |
| Low stock price volatilityVol 12M is 23% | ||
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Precision Medicine, and Digital Health & Telemedicine. Themes include Geriatric Care, Show more. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 28% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14% |
| Low stock price volatilityVol 12M is 23% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Precision Medicine, and Digital Health & Telemedicine. Themes include Geriatric Care, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -31%, 3Y Excs Rtn is -68% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 28x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 47x, P/EPrice/Earnings or Price/(Net Income) is 35x |
| Key risksEW key risks include [1] intense competition in its core TAVR and TMTT markets from major rivals, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Edwards Lifesciences (EW) stock has remained largely at the same level since 10/31/2025 because of the following key factors:
1. Q3 2025 Earnings and Raised Guidance Largely Priced In or Met with Mixed Reactions. Edwards Lifesciences reported strong third-quarter 2025 results on October 30, 2025, exceeding analyst expectations for both earnings per share ($0.67 actual vs. $0.59 consensus) and revenue ($1.55 billion actual vs. $1.5 billion consensus). The company also raised its full-year 2025 adjusted earnings per share guidance and total sales growth guidance. However, the stock's immediate reaction was minimal, with shares edging up only 0.10% following the announcement, and some reports even noted a slight decline in the subsequent trading session. This indicates that the positive financial performance and improved outlook were largely anticipated by the market or offset by other factors, preventing a significant upward stock movement.
2. JenaValve Acquisition Blocked, Leading to Strategic Re-focus. In January 2026, the U.S. District Court for the District of Columbia granted a preliminary injunction requested by the Federal Trade Commission, blocking Edwards Lifesciences' proposed acquisition of JenaValve. Consequently, Edwards exited the JenaValve deal, which was viewed as a strategic decision to refocus capital and resources on its core transcatheter aortic valve replacement (TAVR) and mitral platforms. While this "strategic reset" is anticipated to drive long-term growth, the immediate period likely saw investors processing the implications of the failed acquisition and the company's refined focus, contributing to a stable stock performance rather than a sharp increase or decrease.
Show more
1. Q3 2025 Earnings and Raised Guidance Largely Priced In or Met with Mixed Reactions. Edwards Lifesciences reported strong third-quarter 2025 results on October 30, 2025, exceeding analyst expectations for both earnings per share ($0.67 actual vs. $0.59 consensus) and revenue ($1.55 billion actual vs. $1.5 billion consensus). The company also raised its full-year 2025 adjusted earnings per share guidance and total sales growth guidance. However, the stock's immediate reaction was minimal, with shares edging up only 0.10% following the announcement, and some reports even noted a slight decline in the subsequent trading session. This indicates that the positive financial performance and improved outlook were largely anticipated by the market or offset by other factors, preventing a significant upward stock movement.
2. JenaValve Acquisition Blocked, Leading to Strategic Re-focus. In January 2026, the U.S. District Court for the District of Columbia granted a preliminary injunction requested by the Federal Trade Commission, blocking Edwards Lifesciences' proposed acquisition of JenaValve. Consequently, Edwards exited the JenaValve deal, which was viewed as a strategic decision to refocus capital and resources on its core transcatheter aortic valve replacement (TAVR) and mitral platforms. While this "strategic reset" is anticipated to drive long-term growth, the immediate period likely saw investors processing the implications of the failed acquisition and the company's refined focus, contributing to a stable stock performance rather than a sharp increase or decrease.
Show more
Stock Movement Drivers
Fundamental Drivers
The -1.3% change in EW stock from 10/31/2025 to 1/31/2026 was primarily driven by a -68.2% change in the company's Net Income Margin (%).| (LTM values as of) | 10312025 | 1312026 | Change |
|---|---|---|---|
| Stock Price ($) | 82.45 | 81.36 | -1.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5,685 | 5,884 | 3.5% |
| Net Income Margin (%) | 72.9% | 23.2% | -68.2% |
| P/E Multiple | 11.7 | 34.9 | 198.5% |
| Shares Outstanding (Mil) | 587 | 585 | 0.4% |
| Cumulative Contribution | -1.3% |
Market Drivers
10/31/2025 to 1/31/2026| Return | Correlation | |
|---|---|---|
| EW | -1.3% | |
| Market (SPY) | 1.5% | 37.3% |
| Sector (XLV) | 7.3% | 40.4% |
Fundamental Drivers
The 2.6% change in EW stock from 7/31/2025 to 1/31/2026 was primarily driven by a 212.9% change in the company's P/E Multiple.| (LTM values as of) | 7312025 | 1312026 | Change |
|---|---|---|---|
| Stock Price ($) | 79.31 | 81.36 | 2.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5,522 | 5,884 | 6.5% |
| Net Income Margin (%) | 75.7% | 23.2% | -69.3% |
| P/E Multiple | 11.1 | 34.9 | 212.9% |
| Shares Outstanding (Mil) | 587 | 585 | 0.4% |
| Cumulative Contribution | 2.6% |
Market Drivers
7/31/2025 to 1/31/2026| Return | Correlation | |
|---|---|---|
| EW | 2.6% | |
| Market (SPY) | 9.8% | 23.0% |
| Sector (XLV) | 19.2% | 31.3% |
Fundamental Drivers
The 12.3% change in EW stock from 1/31/2025 to 1/31/2026 was primarily driven by a 234.9% change in the company's P/E Multiple.| (LTM values as of) | 1312025 | 1312026 | Change |
|---|---|---|---|
| Stock Price ($) | 72.45 | 81.36 | 12.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5,320 | 5,884 | 10.6% |
| Net Income Margin (%) | 78.1% | 23.2% | -70.3% |
| P/E Multiple | 10.4 | 34.9 | 234.9% |
| Shares Outstanding (Mil) | 597 | 585 | 2.1% |
| Cumulative Contribution | 12.3% |
Market Drivers
1/31/2025 to 1/31/2026| Return | Correlation | |
|---|---|---|
| EW | 12.3% | |
| Market (SPY) | 16.0% | 43.7% |
| Sector (XLV) | 6.8% | 41.8% |
Fundamental Drivers
The 6.1% change in EW stock from 1/31/2023 to 1/31/2026 was primarily driven by a 9.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312023 | 1312026 | Change |
|---|---|---|---|
| Stock Price ($) | 76.70 | 81.36 | 6.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5,364 | 5,884 | 9.7% |
| Net Income Margin (%) | 27.2% | 23.2% | -14.7% |
| P/E Multiple | 32.6 | 34.9 | 7.0% |
| Shares Outstanding (Mil) | 620 | 585 | 6.0% |
| Cumulative Contribution | 6.1% |
Market Drivers
1/31/2023 to 1/31/2026| Return | Correlation | |
|---|---|---|
| EW | 6.1% | |
| Market (SPY) | 76.6% | 33.5% |
| Sector (XLV) | 21.4% | 32.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| EW Return | 42% | -42% | 2% | -3% | 15% | -4% | -11% |
| Peers Return | 10% | -7% | 12% | 15% | 6% | -2% | 37% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 86% |
Monthly Win Rates [3] | |||||||
| EW Win Rate | 75% | 33% | 58% | 75% | 58% | 0% | |
| Peers Win Rate | 52% | 50% | 53% | 58% | 57% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| EW Max Drawdown | -14% | -47% | -17% | -22% | -9% | -4% | |
| Peers Max Drawdown | -7% | -22% | -7% | -5% | -7% | -5% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, BSX, ABT, BDX, SYK. See EW Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/30/2026 (YTD)
How Low Can It Go
| Event | EW | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -52.8% | -25.4% |
| % Gain to Breakeven | 111.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -35.3% | -33.9% |
| % Gain to Breakeven | 54.5% | 51.3% |
| Time to Breakeven | 156 days | 148 days |
| 2018 Correction | ||
| % Loss | -20.0% | -19.8% |
| % Gain to Breakeven | 25.1% | 24.7% |
| Time to Breakeven | 106 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -32.0% | -56.8% |
| % Gain to Breakeven | 47.0% | 131.3% |
| Time to Breakeven | 194 days | 1,480 days |
Compare to MDT, BSX, ABT, BDX, SYK
In The Past
Edwards Lifesciences's stock fell -52.8% during the 2022 Inflation Shock from a high on 12/30/2021. A -52.8% loss requires a 111.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Edwards Lifesciences (EW)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
AI Analysis | Feedback
Here are 1-3 brief analogies for Edwards Lifesciences (EW):
- The Intuitive Surgical of heart valves and critical care monitoring.
- Like a Medtronic solely focused on innovative structural heart disease treatments.
- The Abbott Labs of heart valve technology, pioneering minimally invasive replacement procedures.
AI Analysis | Feedback
Here are the major products of Edwards Lifesciences:- Transcatheter Aortic Valve Replacement (TAVR) Systems: Minimally invasive devices used to replace a diseased aortic heart valve without open-heart surgery.
- Surgical Heart Valves: Prosthetic heart valves designed for traditional open-heart surgical replacement of diseased or damaged heart valves.
- Critical Care Technology: Advanced hemodynamic monitoring systems and catheters used to assess cardiovascular function in critically ill patients.
- Transcatheter Mitral and Tricuspid Therapies (TMTT): Developing minimally invasive devices and therapies to treat diseases of the mitral and tricuspid heart valves.
AI Analysis | Feedback
Edwards Lifesciences (symbol: EW) primarily sells its medical devices and technologies to other companies and institutions within the healthcare sector, rather than directly to individual patients.
Their major customers are healthcare providers, which include:
- Hospitals and Hospital Systems: These are the primary purchasers of Edwards' advanced heart valve therapies (including transcatheter aortic valve replacement - TAVR and surgical heart valves) and critical care monitoring products. Hospitals and large integrated health systems perform the surgical and interventional procedures and utilize the monitoring equipment in their operating rooms, intensive care units, and other specialized departments.
- Ambulatory Surgery Centers (ASCs): While the most complex cardiovascular procedures are typically performed in hospitals, some ASCs may utilize Edwards' critical care and patient monitoring solutions for less invasive procedures or specific diagnostic needs.
- Specialized Cardiac Centers and Clinics: These facilities may also purchase specific monitoring equipment or related diagnostic tools from Edwards to support their patient care.
It is important to note that medical device manufacturers like Edwards Lifesciences generally do not disclose specific, named publicly traded "customer companies" with stock symbols in the way a retail product manufacturer might list its major chain store customers. Their sales are distributed across a vast network of thousands of hospitals and healthcare systems globally. Many of these institutions are non-profit or privately owned, and even publicly traded healthcare providers (e.g., Hospital Corporation of America - HCA) are typically one among many institutional purchasers, making it impractical and usually non-disclosed to identify them as "major customers" in the context of publicly listed companies.
AI Analysis | Feedback
nullAI Analysis | Feedback
```htmlBernard J. Zovighian, Chief Executive Officer
Bernard J. Zovighian became CEO of Edwards Lifesciences in May 2023, after serving as the company's president. He joined Edwards Lifesciences in 2015. With a career spanning nearly three decades in medical technology, Zovighian led global businesses across two world-class companies. Prior to joining Edwards, he held roles with increasing responsibilities at Johnson & Johnson (J&J) for almost 20 years, including worldwide president of one of the company's divisions.
Scott B. Ullem, Corporate Vice President, Chief Financial Officer
Scott B. Ullem has served as chief financial officer since 2014, leading Edwards' global finance organization. Before joining Edwards, he was the chief financial officer of Bemis Company Inc., an S&P 500 supplier of packaging and pressure-sensitive materials. Prior to Bemis, Ullem worked as an investment banker for 17 years, holding managing director positions at Goldman Sachs and subsequently at Bank of America, where he advised public and private companies on mergers and acquisitions, as well as equity and debt financing. He currently serves on the board of directors of Illumina and Berry Global.
Donald E. Bobo, Jr., Corporate Vice President, Strategy & Corporate Development
Donald E. Bobo, Jr., has been a corporate vice president since 2007 and is currently responsible for the company's corporate strategy and corporate development functions. He also has executive responsibility for key heart failure initiatives and the U.S. healthcare solutions and commercial services team.
Todd J. Brinton, M.D., F.A.C.C., Corporate Vice President, Advanced Technology & Chief Scientific Officer
Dr. Todd J. Brinton received his bachelor's degree in biomedical engineering from the University of California, San Diego, and his medical degree from the Chicago Medical School at Rosalind Franklin University. He completed his internship, residency, and fellowships in cardiology and interventional cardiology at Stanford. He also serves on the board of directors for the Medical Device Manufacturers Association.
Wayne Markowitz, General Manager and Senior Vice President, Surgical Structural Heart
Wayne Markowitz joined Edwards in August 2023. He has more than 20 years of experience in the medical technology industry, including leadership roles in the U.S., Europe, and Japan. Prior to Edwards, he served as worldwide executive vice president and global head of endovascular robotics at Siemens Healthineers. Before that, Markowitz spent several years in general management and leadership roles at Johnson & Johnson, as well as functional leadership responsibilities at Boston Scientific for a decade.
```AI Analysis | Feedback
Here are the key risks to Edwards Lifesciences (EW):
- Intense Competition: Edwards Lifesciences operates in a highly competitive global medical device market, particularly in its core segments of Transcatheter Aortic Valve Replacement (TAVR), surgical heart valves, and transcatheter mitral and tricuspid therapies (TMTT). Key competitors include Medtronic, Abbott, and Boston Scientific, all of whom invest heavily in research and development and offer competing products. Failure to maintain market leadership or effectively compete with rivals could lead to a loss of market share and reduced profitability.
- Regulatory and Economic Uncertainties: The company faces significant risks from changes in healthcare legislation, reimbursement policies, and broader economic conditions. Macroeconomic factors such as inflationary pressure, supply chain constraints due to geopolitical complications, and staffing shortages within hospital systems can negatively impact Edwards' operating results and pressure its profit margins.
- Need for Continuous Innovation: Edwards Lifesciences' competitive advantage and market position are largely dependent on its proprietary technologies and its ability to continually innovate and introduce new, advanced therapies for structural heart diseases. A failure to invest adequately in research and development or to successfully bring new products to market could result in the loss of its competitive edge and market share, especially as competitors also heavily invest in advancing their own technologies.
AI Analysis | Feedback
nullAI Analysis | Feedback
Edwards Lifesciences (EW) operates in several key markets related to structural heart disease and critical care technologies. Here are the addressable market sizes for their main products and services:
- Transcatheter Aortic Valve Replacement (TAVR): The global TAVR market was estimated at approximately $6.83 billion in 2024 and is projected to grow to about $11.76 billion by 2033, with a compound annual growth rate (CAGR) of 5.99% from 2025 to 2033. Another projection estimates the global TAVR market to reach around $12.5 billion by 2034, up from $6.3 billion in 2024, growing at a CAGR of 7.1%. The worldwide TAVR market is projected to see an 8% CAGR between 2024 and 2034. In the U.S., the market is forecast to grow at a 6% CAGR during the same period.
- Transcatheter Mitral and Tricuspid Therapies (TMTT): The combined market for mitral and tricuspid valves is projected to reach $3 billion by 2025, with mitral therapies constituting the majority. Edwards Lifesciences anticipates capturing a share of the evolving TMTT devices market, which is projected to be $1.0 billion and is expected to grow by 30% annually until 2028. The overall market for Transcatheter Mitral Valve Replacement (TMVR) devices was approximately $1.3 billion in 2024 and is expected to increase to an estimated $3.2 billion by the end of 2030. The global Mitral Valve Disease Market is expected to grow at a CAGR of 8.5% from 2023 to 2032, reaching an anticipated valuation of $6.1 billion by 2032, from $2.9 billion in 2022. Tricuspid interventions are expected to be the fastest-growing segment, with a projected CAGR of 15.15% through 2030.
- Surgical Structural Heart (Surgical Valve Technologies): The surgical structural heart unit is forecast to grow at mid-single-digits, reaching approximately $1 billion in 2024.
Note: Edwards Lifesciences completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) for $4.2 billion in September 2024. Therefore, this is no longer an addressable market for Edwards Lifesciences. The Critical Care business generated over $900 million in revenue globally in 2023.
AI Analysis | Feedback
Edwards Lifesciences (EW) is expected to drive future revenue growth over the next 2-3 years through several key strategies and product advancements, primarily focusing on its leadership in structural heart innovations.Expected Drivers of Future Revenue Growth:
- Continued Expansion and Indication Growth in Transcatheter Aortic Valve Replacement (TAVR): Edwards Lifesciences anticipates sustained growth from its leading TAVR platforms, particularly the SAPIEN 3 platform. The recent FDA approval for asymptomatic severe aortic stenosis, backed by data from the EARLY TAVR trial, is expected to significantly expand the addressable market by reaching a large patient population previously untreated. The company projects continued global adoption and technological advancements within TAVR to be a core driver.
- Accelerated Growth and New Product Launches in Transcatheter Mitral and Tricuspid Therapies (TMTT): The TMTT segment is a major growth engine, with Edwards focusing on the commercialization and global expansion of innovative products such as the EVOQUE tricuspid valve and the PASCAL Precision system. Upcoming regulatory milestones, including the anticipated U.S. approval for the SAPIEN M3 transcatheter mitral valve replacement system in early 2026, are expected to further fuel substantial revenue growth in this area, with TMTT sales projected to reach $2 billion by 2030.
- Increased Adoption of RESILIA Tissue Technology in Surgical Heart Valves: Edwards Lifesciences continues to drive the adoption of its RESILIA portfolio, which includes INSPIRIS, MITRIS, and KONECT valves, setting a new standard for tissue durability in surgical heart valve replacement. The company is committed to advancing its leadership in surgical therapies and expanding access to these innovations in emerging markets globally.
- Entry into Structural Heart Failure Management with the Cordella System: The Cordella system, an implantable heart failure management device approved in 2024, is poised to contribute to future revenue growth. This system allows for real-time monitoring of pulmonary artery pressure, enabling early interventions for heart failure patients. Expected CMS national coverage in early 2025 could significantly expand its market penetration.
- Development of Transcatheter Therapies for Aortic Regurgitation (AR): Edwards is expanding into new therapeutic areas, including aortic regurgitation, a condition with significant unmet needs. The acquisition of JenaValve Technology brings the JenaValve Trilogy System, which could secure FDA approval by late 2025, opening up a new and substantial market for transcatheter AR treatment.
AI Analysis | Feedback
Share Repurchases
- Edwards Lifesciences executed an accelerated share repurchase (ASR) agreement to repurchase $500 million of its common stock in August 2025. This brought total repurchases in 2025 to over $800 million.
- In December 2023, Edwards Lifesciences approved an additional $1 billion share repurchase authorization.
- The company executed an ASR to repurchase $750 million of common stock in November 2022, contributing to over $1.7 billion in share repurchases for that year. Following this, approximately $900 million remained in its share repurchase authorization. As of August 2025, approximately $600 million remained in the share repurchase authorization.
Outbound Investments
- Edwards Lifesciences acquired JenaValve Technology and Endotronix for a total investment of $1.2 billion, with these acquisitions closing in 2024. These investments are part of a focus on structural heart failure and aortic regurgitation.
- The company has made 12 investments across sectors such as Cardiac and Vascular Disorders, Neurology, and Pulmonology, with notable recent investments including Corvia Medical (Series C, June 2022), V-Wave, and Caption Health.
- In 2024, Edwards made a strategic decision to sell its Critical Care product group for $4.2 billion in cash to BD, ensuring a more agile focus on structural heart innovation.
Capital Expenditures
- Edwards Lifesciences' capital expenditures were approximately $325.8 million in 2021, $244.6 million in 2022, $253 million in 2023, and $252.4 million in 2024.
- The average capital expenditures for the fiscal years ending December 2020 to 2024 were $296.6 million.
- The company invested significantly in both internal research and development and external early-stage acquisitions in 2024 to advance novel therapies within its structural heart portfolio.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 106.13 |
| Mkt Cap | 135.3 |
| Rev LTM | 23,110 |
| Op Inc LTM | 4,252 |
| FCF LTM | 3,850 |
| FCF 3Y Avg | 2,951 |
| CFO LTM | 4,729 |
| CFO 3Y Avg | 3,679 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.4% |
| Rev Chg 3Y Avg | 4.7% |
| Rev Chg Q | 9.3% |
| QoQ Delta Rev Chg LTM | 2.2% |
| Op Mgn LTM | 19.3% |
| Op Mgn 3Y Avg | 18.3% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 20.1% |
| CFO/Rev 3Y Avg | 19.1% |
| FCF/Rev LTM | 15.4% |
| FCF/Rev 3Y Avg | 14.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 135.3 |
| P/S | 5.1 |
| P/EBIT | 25.6 |
| P/E | 34.8 |
| P/CFO | 25.1 |
| Total Yield | 4.0% |
| Dividend Yield | 1.5% |
| FCF Yield 3Y Avg | 2.7% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.5% |
| 3M Rtn | 1.3% |
| 6M Rtn | 0.4% |
| 12M Rtn | -6.7% |
| 3Y Rtn | 18.0% |
| 1M Excs Rtn | 0.1% |
| 3M Excs Rtn | -1.4% |
| 6M Excs Rtn | -10.9% |
| 12M Excs Rtn | -21.7% |
| 3Y Excs Rtn | -50.5% |
Price Behavior
Price Behavior
| Market Price | $81.36 | |
| Market Cap ($ Bil) | 47.6 | |
| First Trading Date | 03/27/2000 | |
| Distance from 52W High | -6.4% | |
| 50 Days | 200 Days | |
| DMA Price | $84.70 | $79.24 |
| DMA Trend | up | up |
| Distance from DMA | -3.9% | 2.7% |
| 3M | 1YR | |
| Volatility | 19.6% | 23.2% |
| Downside Capture | 90.61 | 48.87 |
| Upside Capture | 75.10 | 53.19 |
| Correlation (SPY) | 36.2% | 43.8% |
EW Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.75 | 0.76 | 0.64 | 0.43 | 0.52 | 0.70 |
| Up Beta | 2.41 | 1.41 | 0.55 | 0.54 | 0.54 | 0.66 |
| Down Beta | 0.25 | 0.47 | 0.29 | 0.43 | 0.52 | 0.56 |
| Up Capture | 12% | 46% | 74% | 32% | 41% | 46% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 7 | 18 | 29 | 61 | 122 | 367 |
| Down Capture | 144% | 116% | 91% | 45% | 60% | 97% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 13 | 23 | 32 | 64 | 127 | 381 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EW | |
|---|---|---|---|---|
| EW | 14.9% | 23.3% | 0.53 | - |
| Sector ETF (XLV) | 7.7% | 17.2% | 0.27 | 42.2% |
| Equity (SPY) | 16.1% | 19.2% | 0.65 | 43.7% |
| Gold (GLD) | 76.5% | 23.4% | 2.38 | -6.8% |
| Commodities (DBC) | 11.1% | 15.9% | 0.48 | 3.8% |
| Real Estate (VNQ) | 5.3% | 16.5% | 0.14 | 37.5% |
| Bitcoin (BTCUSD) | -18.9% | 39.9% | -0.43 | 18.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EW | |
|---|---|---|---|---|
| EW | -1.0% | 32.3% | 0.04 | - |
| Sector ETF (XLV) | 7.1% | 14.5% | 0.31 | 45.2% |
| Equity (SPY) | 14.0% | 17.1% | 0.65 | 45.0% |
| Gold (GLD) | 20.8% | 16.5% | 1.03 | 8.5% |
| Commodities (DBC) | 12.2% | 18.8% | 0.53 | 1.9% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 38.7% |
| Bitcoin (BTCUSD) | 21.1% | 57.5% | 0.56 | 16.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EW | |
|---|---|---|---|---|
| EW | 12.0% | 32.7% | 0.43 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.52 | 54.1% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 52.1% |
| Gold (GLD) | 15.6% | 15.3% | 0.85 | 4.5% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | 12.1% |
| Real Estate (VNQ) | 5.9% | 20.8% | 0.25 | 41.7% |
| Bitcoin (BTCUSD) | 71.5% | 66.4% | 1.11 | 10.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/30/2025 | -1.2% | -1.2% | 1.5% |
| 7/24/2025 | 5.5% | 4.6% | 8.0% |
| 4/23/2025 | 6.6% | 7.1% | 6.1% |
| 2/11/2025 | 6.9% | 5.3% | -4.2% |
| 10/24/2024 | -1.4% | -4.7% | 0.2% |
| 4/25/2024 | -1.8% | -3.4% | -0.0% |
| 2/6/2024 | -1.9% | -2.3% | 6.3% |
| 10/25/2023 | -8.1% | -6.6% | -0.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 11 | 11 |
| # Negative | 13 | 12 | 12 |
| Median Positive | 3.4% | 3.9% | 4.3% |
| Median Negative | -5.6% | -4.0% | -6.1% |
| Max Positive | 6.9% | 7.3% | 8.0% |
| Max Negative | -17.9% | -20.4% | -18.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 04/29/2024 | 10-Q |
| 12/31/2023 | 02/12/2024 | 10-K |
| 09/30/2023 | 10/27/2023 | 10-Q |
| 06/30/2023 | 07/28/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 02/13/2023 | 10-K |
| 09/30/2022 | 10/28/2022 | 10-Q |
| 06/30/2022 | 07/29/2022 | 10-Q |
| 03/31/2022 | 04/28/2022 | 10-Q |
| 12/31/2021 | 02/14/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bobo, Donald E Jr | CVP,Strategy/Corp Development | Direct | Sell | 1062026 | 85.66 | 11,340 | 971,429 | 2,730,132 | Form |
| 2 | Bobo, Donald E Jr | CVP,Strategy/Corp Development | Direct | Sell | 12122025 | 83.76 | 11,386 | 953,748 | 3,264,308 | Form |
| 3 | Lippis, Daniel J | CVP, JAPAC | Direct | Sell | 12122025 | 84.03 | 1,019 | 85,625 | 1,848,792 | Form |
| 4 | Stone, Heisz Leslie | Direct | Sell | 12122025 | 83.41 | 2,615 | 218,120 | 2,581,401 | Form | |
| 5 | Chopra, Daveen | CVP, TMTT & Surgical | Direct | Sell | 12112025 | 84.38 | 2,000 | 168,750 | 2,716,963 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.